CD4 and head and neck cancer: This view fits with previous studies showing no [6, 7] or a positive [8, 10] prognostic effect of Foxp3+ Tregs in head and neck cancer, as here the number of co-infiltrating (activated) CD4+ and CD8+ T cells is also much higher than that of Tregs.